Featured

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450

AEON Biopharma announced that the FDA has scheduled a Biosimilar Biological Product Development (BPD) Type 2a meeting for ABP-450 (prabotulinumtoxinA)...

Home/KnolSights/Regulatory Approvals/AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450